EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The effects of patient out‐of‐pocket costs on insulin use among people with type 1 and type 2 diabetes with Medicare Advantage insurance—2014–2018

Carrie McAdam-Marx iD, Natalia Ruiz-Negron, Jane M Sullivan, Jamie M Tucker

Health Services Research · 2024

DOI: 10.1111/1475-6773.14152 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Services Research, 2024. Verfasst von Carrie McAdam-Marx und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice & Science, Optum Labs, Visiting Fellow, University of Nebraska Medical Center, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Medicare Part C, Insurance, Insulins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Robert Wood Johnson Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To identify the association between insulin out‐of‐pocket costs (OOPC) and adherence to insulin in Medicare Advantage (MA) patients. Data Sources and Study Setting The study is based on Optum Labs Data Warehouse, a longitudinal, real‐world data asset with de‐identified administrative claims and electronic health record data. Study Design Using descriptive and multivariable logistic regression analyses, we identified the likelihood of patients with diabetes having ≥60 consecutive days between an expected insulin fill date and the actual fill date (refill lapse) by OOPC, categorized by $0, >$0–$20 (reference), >$20–$35, >$35–$50, and > $50 per 30‐day supply. Data Collection/Extraction Methods The study included MA enrollees with type 1 or type 2 diabetes and prescription claims for insulin between 2014 and 2018. Principal Findings Those with average insulin OOPC per 30‐day supply >$35 or $0 were more likely to have an insulin refill lapse versus OOPC of >$0 to $20, with odds ratios ranging 1.18 (95% CI 1.13–1.22) to 1.74 (95% CI 1.66–1.83) depending on OOPC group and diabetes type.

Conclusions

Capping average insulin OOPC at $35 per 30‐day supply may help avoid cost‐related insulin non‐adherence in MA patients; efforts to address non‐cost barriers to medication adherence remain important.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Medicare Part CInsuranceInsulinsHumansAgedUnited StatesHealth ExpendituresPhosphorylcholine

Stichwörter der Autor:innen

Medicare Advantagecost-sharediabetesinsulinmedication adherence

Substanzen

InsulinsoleyloxyethylphosphorylcholinePhosphorylcholine

Autor:innen und Institutionen

  • Department of Pharmacy Practice & Science, Optum Labs, Visiting Fellow, University of Nebraska Medical Center, Omaha, Nebraska, USA.
  • Department of Pharmacotherapy, University of Utah Pharmacotherapy Outcomes Research Center, Salt Lake City, Utah, USA.
  • Optum Labs, Eden Prairie, Minnesota, USA.

ORCID-Profile: Carrie McAdam-Marx

Förderung

  • Robert Wood Johnson Foundation

Zitieren

APA

McAdam-Marx, C., Ruiz-Negron, N., Sullivan, J. M., & Tucker, J. M. (2024). The effects of patient out‐of‐pocket costs on insulin use among people with type 1 and type 2 diabetes with Medicare Advantage insurance—2014–2018. Health Services Research. https://doi.org/10.1111/1475-6773.14152

Vancouver

McAdam-Marx C, Ruiz-Negron N, Sullivan JM, Tucker JM. The effects of patient out‐of‐pocket costs on insulin use among people with type 1 and type 2 diabetes with Medicare Advantage insurance—2014–2018. Health Services Research. 2024. doi:10.1111/1475-6773.14152

BibTeX
@article{McAdamMarx2024,
  author = {McAdam-Marx, Carrie and Ruiz-Negron, Natalia and Sullivan, Jane M and Tucker, Jamie M},
  title = {The effects of patient out‐of‐pocket costs on insulin use among people with type 1 and type 2 diabetes with Medicare Advantage insurance—2014–2018},
  journal = {Health Services Research},
  year = {2024},
  doi = {10.1111/1475-6773.14152}
}
Kostenlos starten →